|
Volumn 119, Issue 6, 2009, Pages 1400-
|
Good and bad news for an antiangiogenic
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BEVACIZUMAB;
PLATELET DERIVED GROWTH FACTOR C;
PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;
PROLYLHYDROXYLASE DOMAIN PROTEIN 2;
RGS PROTEIN;
RGS5 PROTEIN;
UNCLASSIFIED DRUG;
VASCULOTROPIN;
VASCULOTROPIN A;
ANTIANGIOGENIC ACTIVITY;
CANCER RECURRENCE;
CELL FUNCTION;
CLINICAL TRIAL;
COLON CANCER;
COLORECTAL CANCER;
DRUG APPROVAL;
ENDOTHELIUM CELL;
FOOD AND DRUG ADMINISTRATION;
GLIOBLASTOMA;
HUMAN;
LUNG NON SMALL CELL CANCER;
METASTASIS;
NOTE;
OVERALL SURVIVAL;
PERICYTE;
PRIORITY JOURNAL;
PROGNOSIS;
RECURRENCE RISK;
RETINA MACULA AGE RELATED DEGENERATION;
TUMOR VASCULARIZATION;
ANGIOGENESIS INHIBITORS;
HUMANS;
NEOPLASMS;
|
EID: 67651005852
PISSN: 00219738
EISSN: 15588238
Source Type: Journal
DOI: 10.1172/JCI39834 Document Type: Note |
Times cited : (3)
|
References (7)
|